{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=One+cycle&page=33",
    "query": {
      "intervention": "One cycle",
      "page": 33
    },
    "page_size": 10
  },
  "pagination": {
    "page": 33,
    "page_size": 10,
    "total_count": 2770,
    "total_pages": 277,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=One+cycle&page=34&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=One+cycle&page=32&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T02:40:57.998Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05377242",
      "title": "Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gulf War Illness"
      ],
      "interventions": [
        {
          "name": "Curcumin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Resveratrol",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Stinging Nettle",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 390,
      "start_date": "2023-05-31",
      "completion_date": "2026-06-22",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-10-30T02:40:57.998Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05377242"
    },
    {
      "nct_id": "NCT01867086",
      "title": "Salvage Ovarian FANG™ Vaccine + Carboplatinum",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Ovarian Cancer",
        "Stage IV Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Vigil™ Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatinum",
          "type": "DRUG"
        },
        {
          "name": "Carboplatinum and Taxol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gradalis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2013-06",
      "completion_date": "2016-04-08",
      "has_results": true,
      "last_update_posted_date": "2018-06-19",
      "last_synced_at": "2026-10-30T02:40:57.998Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01867086"
    },
    {
      "nct_id": "NCT00388505",
      "title": "Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Tobramycin Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "Tobramycin Solution for Inhalation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 517,
      "start_date": "2006-02",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2012-07-24",
      "last_synced_at": "2026-10-30T02:40:57.998Z",
      "location_count": 24,
      "location_summary": "Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 21 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00388505"
    },
    {
      "nct_id": "NCT02846766",
      "title": "Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teresa Helsten, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-07-01",
      "completion_date": "2021-06-01",
      "has_results": false,
      "last_update_posted_date": "2018-08-02",
      "last_synced_at": "2026-10-30T02:40:57.998Z",
      "location_count": 2,
      "location_summary": "La Jolla, California • Chicago, Illinois",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02846766"
    },
    {
      "nct_id": "NCT07851727",
      "title": "Gastric Focused Ultrasound Stimulation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gastroparesis",
        "Delayed Gastric Emptying"
      ],
      "interventions": [
        {
          "name": "Gastric Focused Ultrasound Stimulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Evan (Huiliang) Wang",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 12,
      "start_date": "2026-09-11",
      "completion_date": "2027-09-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-30T02:40:57.998Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07851727"
    },
    {
      "nct_id": "NCT03324373",
      "title": "Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Partial or Radical Cytoreductive Nephrectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Yousef Zakharia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2019-03-20",
      "completion_date": "2024-08-28",
      "has_results": false,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-10-30T02:40:57.998Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03324373"
    },
    {
      "nct_id": "NCT01118273",
      "title": "Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Sleep"
      ],
      "interventions": [
        {
          "name": "Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg",
          "type": "DRUG"
        },
        {
          "name": "Naproxen Sodium 440 mg (BAYH6689)",
          "type": "DRUG"
        },
        {
          "name": "Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg",
          "type": "DRUG"
        },
        {
          "name": "Naproxen Sodium 220 mg (BAYH6689)",
          "type": "DRUG"
        },
        {
          "name": "DPH 50mg",
          "type": "DRUG"
        },
        {
          "name": "Ibuprofen 400 mg / Diphenhydramine citrate 76 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "16 Years to 45 Years"
      },
      "enrollment_count": 162,
      "start_date": "2008-01",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2015-06-08",
      "last_synced_at": "2026-10-30T02:40:57.998Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01118273"
    },
    {
      "nct_id": "NCT04017546",
      "title": "CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AML",
        "MDS"
      ],
      "interventions": [
        {
          "name": "CYC065",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cyclacel Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2019-08-02",
      "completion_date": "2023-04-05",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-30T02:40:57.998Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04017546"
    },
    {
      "nct_id": "NCT04872166",
      "title": "A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "BTX-A51",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Edgewood Oncology Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2021-06-07",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2025-01-30",
      "last_synced_at": "2026-10-30T02:40:57.998Z",
      "location_count": 6,
      "location_summary": "Lake Mary, Florida • Sarasota, Florida • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04872166"
    },
    {
      "nct_id": "NCT00964366",
      "title": "Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "clindamycin and benzoyl peroxide",
          "type": "DRUG"
        },
        {
          "name": "Dapsone gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stiefel, a GSK Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 53,
      "start_date": "2009-07",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-10-30T02:40:57.998Z",
      "location_count": 1,
      "location_summary": "Broomall, Pennsylvania",
      "locations": [
        {
          "city": "Broomall",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00964366"
    }
  ]
}